JP6368459B2 - 点眼液の製造方法 - Google Patents
点眼液の製造方法 Download PDFInfo
- Publication number
- JP6368459B2 JP6368459B2 JP2013125089A JP2013125089A JP6368459B2 JP 6368459 B2 JP6368459 B2 JP 6368459B2 JP 2013125089 A JP2013125089 A JP 2013125089A JP 2013125089 A JP2013125089 A JP 2013125089A JP 6368459 B2 JP6368459 B2 JP 6368459B2
- Authority
- JP
- Japan
- Prior art keywords
- oxygen
- water
- mixing
- pins
- center
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 55
- 239000002997 ophthalmic solution Substances 0.000 title claims description 51
- 229940054534 ophthalmic solution Drugs 0.000 title claims description 51
- 239000001301 oxygen Substances 0.000 claims description 298
- 229910052760 oxygen Inorganic materials 0.000 claims description 298
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 294
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 228
- 238000002156 mixing Methods 0.000 claims description 199
- 230000002093 peripheral effect Effects 0.000 claims description 16
- 238000007599 discharging Methods 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 239000003889 eye drop Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 230000005484 gravity Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 229940012356 eye drops Drugs 0.000 description 8
- 208000027993 eye symptom Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 150000002926 oxygen Chemical class 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 230000010349 pulsation Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 206010052140 Eye pruritus Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000005111 ocular hyperemia Diseases 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008400 supply water Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
Description
図2において、当該多数のピンP1〜P8は、複数(図示では8つ)の同心円の円周上に配置されている。
中心点Oに最も近接しているピンP1は、点Oを中心とするピッチ円の円周上に等間隔に10本配置されている。
例えば、R=45mmの場合、φ1=7mmである。そして、ピンP1の直径D1は、例えば2.0mmである。
例えば、R=45mmの場合、φ2=9mmである。そして、ピンP2の直径D2は、例えば2.5mmである。
例えば、R=45mmの場合、φ3=16mmである。そして、ピンP3の直径D3は、例えば4.0mmである。
例えば、R=45mmの場合、φ4=21mmである。
例えば、R=45mmの場合、φ5=27mmである。
例えば、R=45mmの場合、φ6=31mmである。
例えば、R=45mmの場合、φ7=37mmである。
例えば、R=45mmの場合、φ8=42mmである。
図9に概略を示した酸素水の製造システム、製造された酸素水の特徴を確認するための実験を行った。
さらに、上記<1>と同様の方法で製造された酸素水と、市販品の酸素水との比較実験を行った。
上記<1>と同様の方法で製造された酸素水を点眼液としてそのまま使用し、被験者の症状の変化を検討した。
<4>比重の測定
上記<1>と同様の方法で製造された酸素水について比重の測定を行った。
2 凹部
3 中央部
4 貫通孔
5 ケーシング/供給側のケーシング
6 ケーシング/吐出側のケーシング
7 供給管
8 吐出管
10 混合装置
20 蓋部
100 酸素水製造システム
G 混合部
M 主体
P、P1〜P8 ピン
Claims (1)
- 酸素と水を混合する円盤状の混合部を備えた混合装置と加圧手段とを含む酸素水の製造システムによる、
(A)解放された大気下において、溶存酸素濃度が25ppm以上の状態が35日以上持続する酸素水を含む点眼液、または
(B)解放された大気下において、溶存酸素濃度が25ppm以上の状態が35日以上持続する酸素水のみからなる点眼液の製造方法であって、
混合装置の混合部は、
供給孔と、
排出孔と、
供給孔と排出孔を連通する流路、および
流路から突出し、供給された水との接触に伴って超音波振動する、円柱形の複数のピン
を有し、
混合部の中央付近に供給孔、外周縁付近に排出孔、または、中央付近に排出孔、外周縁付近に供給孔が配置され、
同心の仮想円上に複数配置されたピンによって形成される環状列が、混合部の中央から外周縁へ向かって複数列配置され、ピンが混合部の中央から外周縁へ向かって放射状に配置されており、
ピンは、直径Dが、
0.004R≦D≦0.089R(Rは、混合部の半径を示す)
であるものを含み、
加圧手段によって酸素を含む水を0.1Mpa以上の圧力で供給孔から流路へと供給し、ピンとの接触を伴って酸素を含む水が流路を通過し、ピンが超音波振動することで酸素と水とが混合されて生成された酸素水が排出孔から排出される工程を含むことを特徴とする点眼液の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013125089A JP6368459B2 (ja) | 2012-06-14 | 2013-06-13 | 点眼液の製造方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012135247 | 2012-06-14 | ||
JP2012135247 | 2012-06-14 | ||
JP2013125089A JP6368459B2 (ja) | 2012-06-14 | 2013-06-13 | 点眼液の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014015455A JP2014015455A (ja) | 2014-01-30 |
JP6368459B2 true JP6368459B2 (ja) | 2018-08-01 |
Family
ID=50110478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013125089A Active JP6368459B2 (ja) | 2012-06-14 | 2013-06-13 | 点眼液の製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6368459B2 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001267851A1 (en) * | 2000-06-29 | 2002-01-08 | Rohto Pharmaceutical Co., Ltd. | Oxygen-containing ophthalmic composition |
US20080057023A1 (en) * | 2006-08-29 | 2008-03-06 | Chynn Emil W | Oxygenated ophthalmic composition |
CN101910412B (zh) * | 2007-10-25 | 2013-08-21 | 利发利希奥公司 | 调节细胞膜介导的细胞内信号转导的组合物和方法 |
-
2013
- 2013-06-13 JP JP2013125089A patent/JP6368459B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014015455A (ja) | 2014-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8591957B2 (en) | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution | |
US7654728B2 (en) | System and method for therapeutic application of dissolved oxygen | |
US10479979B2 (en) | Method for making and using cold atmospheric plasma stimulated media for cancer treatment | |
US20100297193A1 (en) | Methods of therapeutic treatment of eyes | |
US10556256B2 (en) | Antibacterial water | |
KR102162400B1 (ko) | 생체 투여 가능한 수용액 및 그 제조 방법 | |
JP6367519B2 (ja) | 混合装置、混合流体製造装置、混合流体の製造方法とこれによって製造された混合流体、および酸素を含む水、氷 | |
JP2010508087A5 (ja) | ||
Elashiry et al. | Exogenous and endogenous dendritic cell-derived exosomes: Lessons learned for immunotherapy and disease pathogenesis | |
WO2009070739A2 (en) | Systems, devices, and methods for directly energizing water molecule composition | |
JP6368459B2 (ja) | 点眼液の製造方法 | |
JP2016532683A (ja) | 海馬の可塑性ならびに海馬依存性学習及び記憶を上方制御するための組成物及び方法 | |
JP6159584B2 (ja) | 輸液、輸液の製造方法および輸液装置 | |
JP5934735B2 (ja) | ナノバブル・フコイダン水素水 | |
JP2014014357A (ja) | 肝機能・腎機能改善飲料およびこの製造方法 | |
JP2014015457A (ja) | 睡眠時無呼吸症候群緩和液および睡眠時無呼吸症候群緩和液の製造方法 | |
JP2014014358A (ja) | 酸素含有培地溶解液、細胞培養培地、細胞培養方法および酸素含有培地溶解液の製造システム | |
Kakumanu et al. | Focused Ultrasound A Novel Tool for liposome formulation | |
JP6728555B2 (ja) | 化粧料 | |
Ming et al. | A mini review of S-Nitrosoglutathione loaded nano/micro-formulation strategies | |
JP2024034862A (ja) | 薬液注入装置 | |
Lancina et al. | Dendrimer Nanofibers for Ocular Drug Delivery | |
JP2019162606A (ja) | 微細気泡発生装置とその方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180620 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180703 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180709 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6368459 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |